Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Key Points

• Short interest fell 32.5% to 109,877 shares as of April 15, representing about 0.3% of the stock sold short and a days-to-cover ratio of 3.3 days.
• Kamada missed Q results, reporting $0.06 EPS vs. $0.09 expected and $44.68M revenue vs. $145.07M expected; the stock traded around $8.15 (52-week range $6.35–$9.35) and carries a MarketBeat consensus rating of "Moderate Buy" with a $13 price target.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) was the target of a large drop in short interest in April. As of April 15th, there was short interest totaling 109,877 shares, a drop of 32.5% from the March 31st total of 162,767 shares. Currently, 0.3% of the company's stock are sold short. Based on an average daily volume of 33,390 shares, the days-to-cover ratio is currently 3.3 days.

Kamada Price Performance

NASDAQ:KMDA traded down $0.05 during midday trading on Tuesday, reaching $8.15. The stock had a trading volume of 22,146 shares, compared to its average volume of 38,089. Kamada has a 1-year low of $6.35 and a 1-year high of $9.35. The firm's fifty day simple moving average is $8.57 and its 200-day simple moving average is $7.79. The stock has a market capitalization of $468.71 million, a P/E ratio of 23.43, a PEG ratio of 0.63 and a beta of 0.93.

Kamada (NASDAQ:KMDA - Get Free Report) last posted its earnings results on Wednesday, March 11th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.03). Kamada had a net margin of 11.19% and a return on equity of 7.72%. The firm had revenue of $44.68 million during the quarter, compared to analyst estimates of $145.07 million. On average, equities research analysts anticipate that Kamada will post 0.52 earnings per share for the current fiscal year.

Kamada Dividend Announcement

The business also recently declared an annual dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were given a $0.25 dividend. This represents a yield of 305.0%. The ex-dividend date was Monday, March 23rd. Kamada's dividend payout ratio (DPR) is currently 54.29%.

Institutional Trading of Kamada

Several hedge funds and other institutional investors have recently bought and sold shares of KMDA. Cubist Systematic Strategies LLC acquired a new stake in Kamada in the 1st quarter worth $206,000. NewEdge Advisors LLC grew its position in Kamada by 119.9% in the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock worth $341,000 after purchasing an additional 28,165 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Kamada in the 1st quarter worth $497,000. Jane Street Group LLC acquired a new stake in Kamada in the 1st quarter worth $582,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Kamada in the 2nd quarter worth $472,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KMDA has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Kamada from a "strong-buy" rating to a "buy" rating in a research note on Saturday, March 14th. Stifel Nicolaus set a $11.00 target price on shares of Kamada in a research note on Wednesday, March 11th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Kamada in a research note on Thursday, January 22nd. Finally, Benchmark reiterated a "buy" rating on shares of Kamada in a research note on Thursday, March 12th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $13.00.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.